119-HR1432

LIABLE Act

Last action was on 2-18-2025

Bill is currently in: House
Path to Law
House Senate President

Current status is Referred to the House Committee on the Judiciary.

View Official Bill Information at congress.gov

No users have voted for/against support on this bill yet. Be the first!


119th CONGRESS

1st Session

H. R. 1432

1. Short title
2. No Federal immunity from, or limitation on, liability for manufacturers for loss caused by a COVID–19 vaccine

1. Short title

This Act may be cited as the "Let Injured Americans Be Legally Empowered Act" or the "LIABLE Act".


2. No Federal immunity from, or limitation on, liability for manufacturers for loss caused by a COVID–19 vaccine

(a) In general - No Federal law, including sections 319F–3, 2111, and 2122 of the Public Health Service Act (42 U.S.C. 247d–6d, 300aa–11, 300aa–22), may make the manufacturer of a COVID–19 vaccine immune from suit or liability, or limit the liability of such a manufacturer, with respect to claims for loss caused by, arising out of, relating to, or resulting from the administration to or the use by an individual of a COVID–19 vaccine.

(b) Rule of construction - Nothing in this Act shall be construed to prohibit an individual from seeking compensation through the Countermeasures Injury Compensation Program under section 319F–4 of the Public Health Service Act (42 U.S.C. 247d–6e) or the National Vaccine Injury Compensation Program under subtitle 2 of title XXI of such Act (42 U.S.C. 300aa–10 et seq.).

(c) Relation to other programs - An individual shall not be precluded from bringing a civil action for claims described in subsection (a) on the basis of such individual having sought or received compensation through the Countermeasures Injury Compensation Program under section 319F–4 of the Public Health Service Act (42 U.S.C. 247d–6e) or the National Vaccine Injury Compensation Program under subtitle 2 of title XXI of such Act (42 U.S.C. 300aa–10 et seq.).

(d) Definition - The term "COVID–19 vaccine" means a vaccine licensed or otherwise authorized by the Food and Drug Administration to prevent, mitigate, or limit—

(1) - the harm from COVID–19; or

(2) - the transmission of SARS–CoV–2 or a virus mutating therefrom.

(e) Retroactive applicability - This Act applies without regard to whether the adminstration or use of a COVID–19 vaccine occurs before, on, or after the date of enactment of this Act.